Kaiser Permanente
Integrated system (regional formularies) · updated October 13, 2026
Coverage right now
- Foundayo™ (orforglipron) Unknown
- Saxenda® (liraglutide) Varies
- Wegovy® (semaglutide injection) Varies
- Wegovy® tablets (oral semaglutide) Unknown
- Zepbound® (tirzepatide) Varies
Regional variance is the defining feature, and Kaiser runs the strictest step therapy of any major payer: the NW region requires failing TWO oral weight-loss agents AND a 6-month semaglutide trial before Zepbound. California base commercial plans removed Wegovy for BMI < 40 effective 1/1/2025 (employer opt-in otherwise). Formulary exceptions are functionally in-house bariatric-medicine reviews.
Drug status
| Drug | Status | Detail | Confidence |
|---|---|---|---|
| Wegovy® (semaglutide injection) | Varies from Jan 1, 2025 to Sep 30, 2026 | NW: covered only with weight-loss drug benefit + PA + heavy step. CA (NCAL/SCAL): removed from base commercial for BMI < 40 eff 1/1/2025. WA: excluded on most 2026 formularies. Mid-Atlantic: PA per the weight-management form rev 9/22/2025 (eff 10/7/2025). source | high |
| Wegovy® (semaglutide injection) | Varies from Oct 1, 2026 | NW: covered only with weight-loss drug benefit + PA + heavy step. CA (NCAL/SCAL): removed from base commercial for BMI < 40 eff 1/1/2025. WA: no longer excluded — the large-group 4-tier formulary edition effective October 2026 lists WEGOVY SUBCUTANEOUS and WEGOVY HD at Tier 2, both with PA and a quantity limit. That is a better tier than Zepbound's 3, so in WA the step order the NW region imposes is reversed by the formulary. Mid-Atlantic: PA per the weight-management form rev 9/22/2025 (eff 10/7/2025), which also carries a Wegovy-only cardiovascular route that skips the weight-management step therapy but is narrow: age 55 to under 75, BMI 27 or more, a history of diabetes at HbA1c 6.5% or above, an established history of myocardial infarction, and optimisation on statin, antiplatelet and antihypertensive therapy. healthy.kaiserpermanente.org· healthy.kaiserpermanente.org | high |
| Zepbound® (tirzepatide) | Varies from Jun 18, 2026 to Sep 30, 2026 | NW: covered with benefit + PA, last-line after two orals AND >= 6-month semaglutide trial (criteria rev 6/11/2026, eff 6/18/2026). WA: on the large-group 4-tier formulary at Tier 3 with PA and QL, both Zepbound and Zepbound KwikPen — the one region where Zepbound is listed and Wegovy is not. Both documented regions also run a separate obstructive-sleep-apnea route, and at Kaiser it is not the easier door it is elsewhere: NW asks for severe OSA at an AHI of 30 or more with a sleep study inside 5 years, MAS asks for a baseline BMI >= 35, and each still demands the full step therapy underneath. Unlike the weight-management route, the NW OSA criteria do not themselves require a benefit covering weight-loss drugs. source | high |
| Zepbound® (tirzepatide) | Varies from Oct 1, 2026 | NW: covered with benefit + PA, last-line after two orals AND >= 6-month semaglutide trial. The criteria rev 6/11/2026 (eff 6/18/2026) govern until 12/16/2026; the rev 9/10/2026 revision this file previously tracked for 11/05/2026 is gone from the URL without ever taking effect, replaced by a rev 10/08/2026 one effective 12/17/2026, so the handover a reader was told to expect on 11/05/2026 now falls on 12/17/2026. Every criterion a reader acts on is identical in the new one — the 12-month initial approval, the two-oral step, the 6-month semaglutide trial with a bariatric-medicine chart review, the BMI 30 / 27-with-comorbidity thresholds and the 5% reauthorisation were all re-read in full on 2026-10-23 and none moved. Quote the 10/08/2026 stamp in an appeal filed on or after 12/17/2026; the document prints it as 'Revised: 10/080/26', which is a typo in Kaiser's own header and not a different document. WA: on the large-group 4-tier formulary at Tier 3 with PA and QL, both Zepbound and Zepbound KwikPen — and from the October 2026 edition Wegovy sits a tier above it at 2, so WA no longer reaches Zepbound ahead of Wegovy. Both documented regions also run a separate obstructive-sleep-apnea route, and at Kaiser it is not the easier door it is elsewhere: NW asks for severe OSA at an AHI of 30 or more, a sleep study inside 5 years with no more than 5% body weight lost since it, no central or complex apnea and a BMI of 30 or more; MAS asks for a baseline BMI >= 35 but accepts moderate OSA at an AHI of 15 or more where NW requires severe, and additionally asks that the member either cannot use PAP therapy or has used it for at least 3 months; and each still demands the full step therapy underneath. Unlike the weight-management route, the NW OSA criteria do not themselves require a benefit covering weight-loss drugs. healthy.kaiserpermanente.org· healthy.kaiserpermanente.org | high |
| Wegovy® tablets (oral semaglutide) | Unknown | Not found in retrieved KP formularies/criteria as of Oct 2026 — KP regions typically slow-add. The WA large-group formulary effective October 2026 does list RYBELSUS, but that is the type 2 diabetes semaglutide tablet, not the weight-loss Wegovy tablet, and no weight-loss oral appears on it. source | low |
| Foundayo™ (orforglipron) | Unknown | Not found in retrieved KP documents as of Oct 2026, including the WA large-group formulary effective October 2026; members cited ~$149/month cash option instead. source | low |
| Saxenda® (liraglutide) | Varies | The Mid-Atlantic PA form is one form for Wegovy, Saxenda and Zepbound together, covering commercial, exchange and FEHB plans; WA lists generic liraglutide at Tier 1 with PA and QL. Branded Saxenda is not on the WA large-group formulary. source | high |
What these rules come to in dollars — every dose, priced under this coverage:
- Foundayo 0.8 mg2.5 mg5.5 mg9 mg14.5 mg17.2 mg
- Wegovy 0.25 mg0.5 mg1 mg1.7 mg2.4 mg7.2 mg
- Wegovy® tablets 1.5 mg4 mg9 mg25 mg
- Zepbound 2.5 mg5 mg7.5 mg10 mg12.5 mg15 mg
What preferred, covered and exception only mean
- Preferred
- On the formulary at the plan's best tier for this class. Usually still needs prior authorization — preferred is not the same as automatic.
- Covered
- On the formulary, but not the plan's first choice for this class. Often a higher copay tier than a preferred drug.
- Non preferred
- On the formulary at a disadvantaged tier, or reachable only after trying a preferred drug first.
- Exception only
- Not routinely covered. Obtainable only through a formulary-exception request that meets the plan's published criteria.
- Excluded
- Not on the formulary at all. A benefit exclusion is a different fight from a PA denial and is appealed differently.
- Varies
- The payer's own documents differ by plan or line of business, so a single answer here would be wrong.
- Unknown
- Not yet verified against a primary document. Recorded as absent rather than guessed.
- N/A
- Not applicable to this payer.
Prior authorization criteria
high- PA required
- Yes in all regions where a weight-loss drug benefit exists.
- Initial BMI
- NW: BMI >= 30, or >= 27 with comorbidity. MAS: BMI >= 30 or 27-<30 with >= 1 condition. CA base plans: effectively BMI >= 40 since 1/1/2025.
- Comorbidities
- The NW list differs by drug. NW Zepbound (broad): HTN, diabetes, hyperlipidemia, pre-diabetes, established CVD/stroke, CHF, CKD, NAFLD, OSA, weight-bearing osteoarthritis, PCOS. NW Wegovy is far narrower — HTN, diabetes, hyperlipidemia only, so a BMI 27-29 member qualifying on OSA or PCOS reaches Zepbound's criteria but not Wegovy's.
- Lifestyle requirement
- NW Zepbound: actively making lifestyle modification (diet and/or exercise) or an active behavioral-health referral. NW Wegovy: currently following a diet and exercise program. MAS: enrollment in a program (KP DPP, Weight Watchers, Noom, etc.).
- Initial authorization
- NW 12 · MAS 6
- Reauthorization
- NW: achieved and maintained >= 5% weight loss (12-month cycles). MAS: >= 5% from baseline documented within previous 3 months.
- Step therapy
- STRICTEST OF ANY MAJOR PAYER. NW Wegovy: fail adequate 3-month trials of >= 2 of phentermine/diethylpropion/topiramate/Qsymia/Contrave, then fail semaglutide (Ozempic). NW Zepbound: the two-oral step PLUS a failed minimum 6-month semaglutide trial. MAS: phentermine, topiramate, naltrexone, bupropion, Wegovy, orlistat trials.
- Quantity limits
- QLs flagged; counts not enumerated in public PDFs. WA lists every GLP-1 on the large-group 4-tier formulary with a QL marker.
Primary criteria document: healthy.kaiserpermanente.org· healthy.kaiserpermanente.org· healthy.kaiserpermanente.org
Exceptions and appeals
- Appeal deadline
- 60 days
- Deadline detail
- 60 days from denial for internal appeal (member process); CA IMR after internal exhaustion (immediate if imminent threat).
- Exception route
- MAS: fax the weight-management PA form to 1-844-785-2802 — the form asks the prescriber to return it within 24 hours — and the PA help desk is 1-866-331-2103. All regions: kp.org portal/phone grievance-appeal. CA members: DMHC Independent Medical Review after internal exhaustion, 1-888-466-2219 — binding on KP.
- Turnaround
- Internal appeal: 30 days standard / 72h expedited. DMHC IMR ~30 days / 72h expedited.
- Where
- Region-specific — via kp.org.
Dated changes
- Jan 1, 2025 CA base commercial plans removed Wegovy for BMI < 40 source
- Jan 1, 2026 Medi-Cal carve-out ended weight-loss GLP-1s for KP Medi-Cal members (state action) source
- Jun 18, 2026 NW Zepbound criteria re-issued, keeping the 6-month semaglutide-first step source
- Oct 1, 2026 Wegovy returns to the Kaiser Washington large-group 4-tier formulary at Tier 2 (both Wegovy subcutaneous and Wegovy HD, PA and QL), one tier better than Zepbound source
- Dec 17, 2026 Kaiser Northwest's Zepbound criteria move to the rev 10/08/2026 document — cite that version in an appeal from this date source
Regions: NCAL, SCAL, CO, GA, HI, MAS (MD/DC/VA), NW (OR/SW WA), WA. CO/GA/HI statuses unverified (no regional documents surfaced). For CA members the DMHC Independent Medical Review is the most powerful lever — external, binding, and free.
These are each payer's standard template. Employer plans customize them, so the same PBM can cover a drug for one employer and exclude it for another — a status here is a starting point, not your plan. A benefit exclusion is also a different fight from a PA denial. Always request your own plan's criteria in writing; you are entitled to them.